Danaher Corporation vs iShares MSCI South Korea ETF — how do they compare? Danaher Corporation trades at $219.52 (market cap $152.87B), while iShares MSCI South Korea ETF trades at $177.07 (market cap $26.25B). The key difference: Danaher Corporation is far larger — about 5.8× iShares MSCI South Korea ETF's market cap, and Danaher Corporation pays a 0.74% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and iShares MSCI South Korea ETF for 46 Days on average.
| DHR | EWY | |
|---|---|---|
Market Cap | $152.87B | $26.25B |
Volume | 5,228,698 | 19,056,075 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $219.20 |
52-Week Low | $161.91 | $80.72 |
Typical Hold Time | 69 Days | 46 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →